GlassScriptPhysician profile
Darryl Reaume
NPI 1982668448
$7,921.15
in general payments reported to CMS, 2019-2025
48 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $711 · 2021: $1,399 · 2022: $2,485 · 2023: $1,334 · 2024: $987 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,316 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,315.80 |
| Education | $264.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,490.74 | 2019-2024 | Myrbetriq, Xtandi, Veozah |
| Teleflex LLC | $1,128.17 | 2021-2025 | Urolift, Barrigel |
| Procept Biorobotics Corporation | $754.71 | 2022-2024 | Aquabeam System, Aquabeam Robotic System |
| Rochester Medical Corporation | $423.89 | 2020-2022 | |
| Coloplast Corp | $369.51 | 2019-2025 | |
| Janssen Biotech, INC. | $304.92 | 2019-2023 | Erleada |
| Sumitomo Pharma America, INC. | $293.09 | 2023-2025 | Orgovyx, Gemtesa |
| Boston Scientific Corporation | $249.34 | 2019-2024 | Ams 700 |
| Blue Earth Diagnostics | $225.19 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $220.05 | 2021-2024 | Prolaris |
| Endo Pharmaceuticals INC. | $216.97 | 2019-2023 | Xiaflex |
| Antares Pharma, INC. | $211.08 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Urogen Pharma, INC. | $203.62 | 2023-2024 | Jelmyto |
| Axonics, INC. | $176.94 | 2020-2024 | Axonics, Bulkamid |
| Clarus Therapeutics INC. | $163.65 | 2021 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $161.40 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $156.10 | 2020-2023 | |
| 180 Medical, INC. | $151.19 | 2019-2024 | Cure Catheter, Gentlecath Glide |
| Pfizer INC. | $133.99 | 2019-2024 | |
| Allergan, INC. | $75.19 | 2019-2021 | |
| Halozyme INC | $73.77 | 2023 | |
| Tolmar, INC. | $54.10 | 2024-2025 | Eligard, Jatenzo |
| Abbvie INC. | $47.28 | 2019-2025 | |
| Tolmar Pharmaceuticals, INC. | $45.68 | 2019-2020 | |
| Medtronic, INC. | $44.33 | 2025 | Interstim |
| Olympus America INC. | $42.42 | 2021-2025 | Itind System |
| Medtronic USA, INC. | $36.94 | 2019 | |
| Bk Medical Holding Company INC. | $35.35 | 2021 | |
| Metuchen Pharmaceuticals | $33.81 | 2019 | |
| Dentsply Ih INC. | $33.44 | 2020-2021 | |
| Srs Medical Systems, INC. | $29.69 | 2021-2022 | |
| Agiliti Surgical, INC. | $26.81 | 2023 | Trinity, Sonablate |
| Analogic Corporation | $26.55 | 2019 | |
| Ferring Pharmaceuticals INC. | $25.58 | 2024 | Adstiladrin |
| Photocure INC | $24.20 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $23.30 | 2023 | Bard Urinary Drainage Bag |
| Sun Pharmaceutical Industries INC. | $22.24 | 2023 | Yonsa |
| Verity Pharmaceuticals INC. | $22.04 | 2024 | Tlando |
| Heron Therapeutics, INC. | $20.63 | 2024 | Zynrelef |
| Genzyme Corporation | $19.30 | 2022 | |
| Curium US LLC | $18.85 | 2023 | |
| Cook Medical LLC | $18.40 | 2021 | |
| Merck Sharp & Dohme LLC | $17.79 | 2022 | |
| Endo USA, INC. | $16.28 | 2024 | Xiaflex |
| Dendreon Pharmaceuticals LLC | $13.97 | 2021 | |
| Urovant Sciences INC | $13.61 | 2022 | |
| Telix Pharmaceuticals | $13.25 | 2023 | Illuccix |
| Alnylam Pharmaceuticals INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darryl Reaume listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.